Concord Wealth Partners Agios Pharmaceuticals, Inc. Transaction History
Concord Wealth Partners
- $559 Million
- Q2 2024
A detailed history of Concord Wealth Partners transactions in Agios Pharmaceuticals, Inc. stock. As of the latest transaction made, Concord Wealth Partners holds 200 shares of AGIO stock, worth $9,122. This represents 0.0% of its overall portfolio holdings.
Number of Shares
200
Previous 200
-0.0%
Holding current value
$9,122
Previous $5,000
60.0%
% of portfolio
0.0%
Previous 0.0%
Shares
2 transactions
Others Institutions Holding AGIO
# of Institutions
226Shares Held
56.3MCall Options Held
275KPut Options Held
251K-
Farallon Capital Management LLC San Francisco, CA5.65MShares$258 Million1.18% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.5MShares$251 Million0.0% of portfolio
-
Black Rock Inc. New York, NY4.86MShares$222 Million0.0% of portfolio
-
Bellevue Group Ag Kuesnacht, V83.88MShares$177 Million2.8% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD2.78MShares$127 Million0.01% of portfolio
About AGIOS PHARMACEUTICALS, INC.
- Ticker AGIO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 54,818,000
- Market Cap $2.5B
- Description
- Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of biology. The company offers PYRUKYND (mitapivat) an activator of both wild-type and a variety of mutant pyruvate kinase, PK, enzymes for the treatment of hemolytic anemias; and ...